SCHEMBL3520879

SCHEMBL3520879

O=C(O)c1c(O)ccc2nc(Nc3ccccc3)cnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
PDGFRB P09619 5/20 0.51
PDGFRA P16234 5/20 0.51
HCAR3 P49019 1/20 0.44
RHOA P61586 2/20 0.42
KDM4E B2RXH2 1/20 0.42
PAX8 Q06710 1/20 0.41
DHFR P00374 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CASP3 P42574 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
CDK2 P24941 2/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516845 0.84 EGLN3 (0.57) NPC1RAB9APDGFRBPDGFRARHOA
SCHEMBL3582712 0.81 PDGFRB (0.46) NPC1PDGFRBPDGFRAKDM4EMEN1
SCHEMBL3521287 0.76 ABL1 (0.45) NPC1RAB9APDGFRBKDM4ESMN1; SMN2
SCHEMBL3754497 0.76 PDGFRB (0.56) NPC1RAB9APDGFRBPDGFRARHOA
SCHEMBL3517219 0.74 CA12 (0.37) KDM4EALDH1A1AURKAAURKB
SCHEMBL3520596 0.74 PKMYT1 (0.39) KDM4EALDH1A1SMN1; SMN2
SCHEMBL3530024 0.73 HTT (0.51) NPC1RAB9ARHOAKDM4EMEN1
SCHEMBL3735695 0.71 ALDH1A1 (0.56) RAB9AALDH1A1KMT2ASMN1; SMN2
SCHEMBL29381124 0.71 ALDH1A1 (0.56) RAB9AALDH1A1KMT2ASMN1; SMN2
SCHEMBL1401437 0.70 PDGFRB (0.68) NPC1RAB9APDGFRBPDGFRARHOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 NPC1 2674/4885RAB9A 3111/4885PDGFRB 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.